CLEC5A

Across TCGA pan-cancer cohorts, CLEC5A Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CLEC5A data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CLEC5A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CLEC5A expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, ESCA, and ACC are the cancer types where CLEC5A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.387	0.692	.028	18	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.004	12	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
UCEC	DFS	Median	All	1.000	0.630	.040	2	view →
SKCM	DFS	Median	IV	1.000	0.241	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CLEC5A–OV (OS)

Open the OV breakdown →